INTRACAMERAL DEVICES FOR SUSTAINED DELIVERY

• US 20120245505A1
• Filed: 12/14/2010
• Published: 09/27/2012
• Est. Priority Date: 12/16/2009
• Status: Abandoned Application

• Current Assignee: Alazar N. Ghebremeskel, James A. Burke, Lon T. Spada, Michael R. Robinson, Werhner C. Orilla, Zoran Novakovic
• Original Assignee: Alazar N. Ghebremeskel, James A. Burke, Lon T. Spada, Michael R. Robinson, Werhner C. Orilla, Zoran Novakovic
• Inventors: Robinson, Michael R., Orilla, Werhner C., Novakovic, Zoran, Burke, James A., Ghebremeskel, Alazar N., Spada, Lon T.
• Application Number:
  US13/511,548
• Publication Number:
  US 20120245505A1
• Time in Patent Office: Days
• US Class Current: 604/8
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes

Abstract

Described herein are intracameral drug and/or therapeutic bioactive agent delivery devices comprising a substantially cylindrical structure for at least partial placement into the anterior chamber of an eye The intracameral delivery devices have a sustained release material associated with at least a portion of the device and at least one drug and/or therapeutic bioactive agent associated with said sustained release material.

Claims

1. An intracameral therapeutic agent delivery device comprising:

a substantially cylindrical structure for at least partial placement into the anterior chamber of an eye having a first end, a second end and at least one channel traversing the substantially cylindrical structure, said structure formed of at least one biocompatible non-biodegradable material and having at least one protrusion on an outside surface that prevents migration of said device once implanted and wherein one of said first end and said second end is beveled;

a sustained release material associated with at least a portion of said at least one channel; and

at least one therapeutic bioactive agent associated with said sustained release material.

2. An intracameral therapeutic agent delivery device according to claim 1, wherein at least one of said first end and said second end is sealed with a cap.

3. An intracameral delivery device according to claim 2, wherein the other of said first end and said second end is sealed with a cap.

4. An intracameral therapeutic agent delivery device according to claim 2 or claim 3, wherein said cap is pierceable using a syringe.

5. An intracameral therapeutic agent delivery device according to claim 4, wherein said cap comprises silicone.

6. An intracameral therapeutic agent delivery device according to claim 1, wherein said at least one biocompatible non-biodegradable material is a non-biodegradable polymer, a metal, a metal alloy or a combination thereof.

7. An intracameral therapeutic agent delivery device according to claim 1, wherein said sustained release material is a biodegradable polymer or a polymer matrix.

8. An intracameral therapeutic agent delivery device according to claim 1, wherein said sustained release material is packed into said at least one channel as an implant.

9. An intracameral therapeutic agent delivery device according to claim 1, wherein said sustained release material is coated on the inside surface of said at least one channel.

10. An intracameral therapeutic agent delivery device according to claim 1, wherein said therapeutic bioactive agent is a prostaglandin.

11. An intracameral therapeutic agent delivery device according to claim 1, wherein said substantially cylindrical structure comprises a second channel.

12. An intracameral therapeutic agent delivery device according to claim 11, wherein said second channel is an aqueous shunt

13. An intracameral therapeutic agent delivery device according to claim 12, wherein said second channel is an aqueous shunt having sustained release antifibrotic agent.

14. An intracameral therapeutic agent delivery device according to claim 1, wherein said substantially cylindrical structure has at least one therapeutic bioactive agent releasing pore extending from inside said at least one channel to an environment outside said intracameral therapeutic agent delivery device.

15. A method of treating an ocular condition comprising the steps of:

providing an intracameral therapeutic agent delivery device having a substantially cylindrical structure for at least partial placement into the anterior chamber of an eye having a first end, a second end and at least one channel traversing the substantially cylindrical structure, said structure formed of at least one biocompatible non-biodegradable material and having at least one protrusion on an outside surface that prevents migration of said device once implanted, and wherein one of said first end and said second end is beveled;

a sustained release material associated with at least a portion of said at least one channel; and

at least one therapeutic bioactive agent associated with said sustained release material;

implanting said intracameral therapeutic agent delivery device in an eye wherein at least a portion of said intracameral therapeutic agent delivery device extends into the anterior chamber of said eye;

allowing sufficient time for said therapeutic bioactive agent to migrate from said sustained release material, out of said intracameral therapeutic agent delivery device and into the aqueous humor of said eye; and

treating said ocular condition.

16. The method according to claim 15, wherein said implanting step is performed using an applicator.

17. The method according to claim 15, wherein said ocular condition is selected from the group consisting of aphakia, pseudophakia, astigmatism, blepharospasm, cataract, conjunctival diseases, conjunctivitis, corneal diseases, corneal ulcer, dry eye syndromes, eyelid diseases, lacrimal apparatus diseases, lacrimal duct obstruction, myopia, presbyopia, pupil disorders, refractive disorders, strabismus, glaucoma, ocular hypertension and combinations thereof.

18. The method according to claim 15, wherein said sufficient time is between about 1 month and about 6 months.

19. The method according to claim 15 wherein said at least one biocompatible non-biodegradable material is a non-biodegradable polymer, a metal, a metal alloy or a combination thereof.

20. The method according to claim 15, wherein said sustained release material is a biocompatible polymer packed into said at least on channel as an implant.

21. The method according to claim 15, wherein said therapeutic bioactive agent migrates from said sustained release material, out of said intracameral therapeutic agent delivery device and into the aqueous humor of said eye through at least one therapeutic bioactive agent releasing pore extending from inside said at least one channel to an environment outside said intracameral therapeutic agent delivery device.

22. The method according to claim 15, wherein said environment outside said intracameral therapeutic agent delivery device is the aqueous humor of said eye.

23. The method according to claim 15, wherein at least one of said first end and said second end is sealed with a cap.

24. The method according to claim 15, wherein the other of said first end and said second end is sealed with a cap.

25. The method according to claim 23 or claim 24, wherein said cap is silicone and is pierceable using a syringe.

26. The method according to claim 25 wherein said syringe is used to fill said at least on channel of said intracameral therapeutic agent delivery device with said therapeutic bioactive agent.